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Objectives:  Given  our  previously  published  study,    1 nicotinic  acetylcholine  receptor  (nAChR)  plays  an
essential  role  in nicotine-induced  cell signaling  and  nicotine-induced  resistance  to  epidermal  growth
factor  receptor  tyrosine  kinase  inhibitor  (EGFR-TKI)  in non-small  cell  lung  cancer  (NSCLC)  PC9 cells.  The
aim  of  this  study  was  to investigate  the  potential  mechanism  between  nAChR  and  EGFR  for  nicotine-
induced  resistance  to  EGFR-TKI  erlotinib  in  the  NSCLC  xenograft  model.
Materials  and  methods:  We identiﬁed  the role of  nicotine  to EGFR/AKT/ERK  pathways  and  to  erlotinib-
resistance  in  NSCLC  PC9  and  HCC827  cells  by  MTS  assay  and  western  blot.  Then, we established  the
PC9  xenograft  model  with  nicotine  exposure  and  treated  mice  with  erlotinib  combined  with  vehicle  or
nicotine.
Results:  We  conﬁrmed  the effects  of  nicotine  on  EGFR/AKT/ERK  pathways  and  determined  nicotine’s
potential  in  preventing  from  the  effect  of  erlotinib  on  NSCLC  cells.  Then,  we  showed  that nicotine  expo-on-small cell lung cancer
esistance
sures  can  promote  tumor  growth  and  induce  resistance  to  erlotinib  in  the  PC9  xenograft  model.  Our  results
also indicated  that  chronic  oral  administration  of nicotine  can  cause  more  signiﬁcant  erlotinib-resistance
compared  with  acute  i.v.  injection  of  nicotine  through  activating   1  nAChR  and EGFR  pathways.
Conclusions:  These  results  suggest  that  nicotine  contributes  to the  progression  and  erlotinib-resistance
of  the  NSCLC  xenograft  model  via  the  cooperation  between  nAChR  and  EGFR.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Cigarette smoking has been implicated in the pathogenesis of
ung cancer, in which non-small cell lung cancer (NSCLC) accounts
or 85% [1]. In addition, about one-third of patients with lung cancer
ontinue to smoke after diagnosis [2], not to mention non-smokers
atients with lung cancer exposed to second-hand smoke. Recently,
vidence for an increasing treatment-resistance associated with
igarette smoke exposure has been emerging [3,4].
Nicotine, the major addictive component of cigarette, could con-
ribute to a poor outcome in patients with lung cancer [5–9]. It
as been shown that nicotine can promote the growth and metas-
asis of solid tumors and increase chemotherapeutic resistance
y inducing cell proliferation, invasion, angiogenesis and evasion
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http://creativecommons.org/licenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of apoptosis [10–12]. These effects are due to the activation of
PI3K/AKT, ERK 1/2, MAPK, MEK, NFkB, -arrestin-1, Scr kinase, Rb-
Raf-1 pathways and Bcl-2 family members induced by nicotine
[12–22]. Nicotine is considered as a classical agonist of nicotinic
acetylcholine receptors (nAChRs), which are expressed in neurons
and neuromuscular junctions, as well as in various non-neuronal
cells including endothelial cells and lung cancer cells [14,19,23–25].
nAChRs consist of homo- or hetero-pentamer composed of the var-
ious subunits ( 1– 10;  1– 4; , , ), which are arranged
symmetrically around an axis perpendicular to the membrane to
form classical ligand-gated ion channels.
We have recently characterized muscle-type  1 nAChR
is signiﬁcantly expressed in lung cancer tissues and mediates
nicotine-induced resistance to epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) therapy through cross-talk
with EGFR pathways in PC9 cells [24]. Here, we conﬁrmed the
effects of nicotine on NSCLC PC9 and HCC827 cells in vitro. Then, we
investigated the potential mechanism between nAChR and EGFR
for nicotine-induced resistance to erlotinib (one of representative
EGFR-TKIs) in the PC9 xenograft model.
article under the CC BY-NC-ND license
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. Materials and methods
.1. Cell culture and reagents
Human NSCLC cell lines (PC9, HCC827) and the normal human
ronchial epithelial cell line BEAS-2B were obtained from the Amer-
can Type Culture Collection (Manassas, VA). Cells were cultured
n RPMI 1640 medium (Gibco, Carlsbad, CA) supplemented with
0% fetal bovine serum and 1% penicillin–streptomycin at 37 ◦C in
% carbon dioxide. Nicotine and erlotinib were purchased from
igma–Aldrich Inc. (St. Louis, MO), and Cayman Chemical (Ann
rbor, MI), respectively.
.2. Cell growth assay
Cells were seeded onto 96-well plate, and the following day
rlotinib was added at the indicated concentrations (0–5 M)  in
he presence or absence of nicotine (1 M).  After 72 h, the viability
as determined by MTS  assay (Promega, Madison, WI)  according
o the manufacturer’s instructions.
.3. Tumor xenografts in nude mice
5–6-week old female BALB/cAJc1-nu/nu mice were purchased
rom CLEA Japan, Inc. (Tokyo, Japan). The research protocol was
pproved, and mice were maintained in accordance with the
nstitutional guidelines of Kyushu University Animal Care and
se Committee. Mice received subcutaneous (s.c.) injection with
 × 106 PC9 cells, and then were randomized into four groups
ith treatment by vehicle, nicotine (i.v. injection or oral in the
rinking water) and/or erlotinib for the indicated period. Tumor
ize and mouse weight were measured twice weekly. Tumor
olume was determined using the formula V = ab2/2, where a
nd b are tumor length and width, respectively. Tumor growth
nhibition (TGI, %) for each group was calculated according
o the formula: (TuGcontrol − TuGtest)/TuGcontrol × 100%, where
uG = ﬁnal tumor size − pretreatment tumor size.
.4. Western blotting
Total cell/tumor tissue protein extracts were obtained as pre-
iously described [24,26]. Protein was quantitated with the BCA
ssay (Thermo Scientiﬁc, Rockford, IL). Brieﬂy, lysates adjusted for
rotein concentration were separated on 10% sodium dodecyl sul-
ate polyacrylamide gels and electrotransferred to polyvinylidene
uoride (PVDF) membranes. The transferred membranes were
locked with 3% nonfat milk and incubated with primary anti-
odies overnight at 4 ◦C: total EGFR, AKT, ERK 1/2 (Cell Signaling
echnology, Danvers, CO); phosphorylated EGFR, AKT (Ser-473),
RK 1/2 (Cell Signaling Technology, Danvers, CO);  1 nAChR
Abcam Inc, Cambridge, MA). Then membranes were incubated
ith horseradish peroxidase (HRP)-conjugated secondary antibody
Cell Signaling Inc., Beverly, MA), and visualized using Chemi-
ocXRS (Plus) (Bio-Rad, Hercules, CA).
.5. Quantiﬁcation of cotinine
At the end of the experiment, blood was collected from mice
ia the retro-orbital sinus under anesthesia and sera were prepared
8000 r, 5 min, twice). Serum cotinine (a biomarker for nicotine lev-
ls [27]) levels were determined by using Mouse/Rat Cotinine ELISA
Calbiotech, Spring Valley, CA) following manufacturer’s protocols.r 88 (2015) 1–8
2.6. Statistical analysis
Data are presented as the means ± SEM for three independent
experiments. The 2-tailed Student’s t-test and one-way analysis of
variance (ANOVA) were used for comparison between two groups
or more than three groups. A value of P < 0.05 was considered sig-
niﬁcant.
3. Results
3.1. Nicotine affects EGFR/AKT/ERK pathways via  ˛ 1 nAChR in
NSCLCs
We  examined the expression of  1 nAChR in non-neuronal cells
(NSCLC PC9 and HCC827 cells; positive control: BEAS-2B; Fig. 1A).
Then, we examined the signaling pathways stimulated by nicotine
in NSCLCs. Consistent with previous studies [22,24,28], nicotine
induced dose-dependent phosphorylation of EGFR, AKT (Ser 473)
and ERK in PC9 and HCC827 cells (Fig. 1B and C). Note that high
dose of nicotine (100 M)  decreased the expression of protein
phosphorylation, possibly due to cytotoxicity. Given our previously
published results [24] that show knockdown of  1 nAChR could
reduce protein levels of phosphorylated EGFR/AKT (Ser 473)/ERK
in PC9 cells, these results conﬁrmed that nicotine can induce the
expression of EGFR/AKT/ERK pathways through  1 nAChR.
3.2. Nicotine induces resistance to erlotinib in NSCLCs
We  next investigated the effects of addition of nicotine
to erlotinib on NSCLCs. Fig. 2A showed that erlotinib had a
concentration-dependent inhibition of growth in PC9 and HCC827
cells (EGFR exon 19 deletion), with IC50 values of 0.031 ± 0.0013 M
and 0.046 ± 0.0011 M,  respectively (Fig. 2B). When the cells
were treated with erlotinib plus nicotine (1 M,  72 h, rela-
tively short-term exposure), IC50 values of erlotinib reached
0.043 ± 0.00060 M (PC9; P < 0.05) and 0.14 ± 0.047 M (HCC827),
respectively (Fig. 2B).
To identify the signaling mechanisms of nicotine-induced resis-
tance to erlotinib, we then examined protein levels in cells cultured
for 1 h in the presence or absence of erlotinib (0.01 M/0.1 M)
before exposure to nicotine for additional 1 h. Combined nicotine
with erlotinib (0.01 M)  greatly elevated the protein levels of the
phosphorylation of EGFR/AKT (Ser 473)/ERK, which were inhibited
by erlotinib in PC9 and HCC827 cells (Fig. 3A and B). As the role
of inhibiting phosphorylation by 0.1 M erlotinib was signiﬁcant
in erlotinib-sensitive cells PC9 and HCC827, there is no re-elevated
phosphorylated protein in erlotinib (0.1 M)  plus nicotine. Our pre-
vious study [24] also shows that siRNA against  1 nAChR decreased
the resistance to EGFR-TKI (Calbiochem EMD  Biosciences, La Jolla,
CA) induced by nicotine in PC9 cells. Taken together,  1 nAChR
was involved in nicotine-induced resistance to erlotinib in EGFR
mutant NSCLCs by activating EGFR/AKT/ERK pathways.
3.3. Nicotine promotes tumor growth and induces resistance to
erlotinib in the NSCLC xenograft model
Considering the above ﬁndings that nicotine induces resistance
to erlotinib in vitro, we  assessed the effects of nicotine in the PC9
xenograft model. No substantial weight loss (≥20% of body weight
at start of treatment [29]) was  observed during the treatment
(Fig. 4A).
On day 3 after tumor implantation, mice were treated with
vehicle or nicotine (i.v. injection, 0.6 mg/kg, 5 times/weekly; or
oral in the drinking water, 100 g/mL) for 18 days. Both ways
of exposure to nicotine caused larger tumor size (746 ± 24 mm3,
i.v.; 811 ± 53 mm3, oral) than vehicle (600–630 mm3) (*P < 0.05;
H. Li et al. / Lung Cancer 88 (2015) 1–8 3
Fig. 1. (A) Immunoblot results for  1 nAChR in the NSCLC cells (PC9, HCC827) with EGFR exon 19 deletion and the normal human bronchial epithelial cell line BEAS-2B
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–100  M nicotine for 1 h. Nicotine caused dose-dependent phosphorylation of EGF
f  western blots for the phosphorylated protein. *P < 0.05 compared with 0 M nico
ig. 4B). On day 21 after implantation, mice were treated with vehi-
le, erlotinib (100 mg/kg/day, gavage), erlotinib plus nicotine (i.v.)
r erlotinib plus nicotine (oral) for additional 10 days, respectively.
t the end of the study, erlotinib (100 mg/kg) signiﬁcantly reduced
he tumor size by 100% of the tumor regression (219 ± 39 mm3,
GI % = −65.28%, P < 0.05; Fig. 4B and C) compared with vehicle
reatment (1234 ± 33 mm3). The addition of nicotine to erlotinib
reatment showed much lower antitumor activity compared with
rlotinib alone (	P < 0.05; Fig. 4B), with TGI % of −22.46% (nicotine,
.v.) and 11.31% (nicotine, oral), respectively (Fig. 4C). Interestingly,
hronic oral administration of nicotine prevented from erlotinib
eduction on tumor size more signiﬁcantly than acute i.v. injec-
ion of nicotine at the end of the treatment (P < 0.05), although
e observed the similar inductive effect to tumor size by these two
ays of nicotine administration shown above.
.4. Concentrations of cotinine in mouse serum
Cotinine is proportional to the quantity of nicotine absorbed
ecause of the long half-life [15,27,30]. Therefore, we  collected
lood in mice 30 min  [31] after administrating nicotine on the last
ay of treatment, and examined cotinine levels in the mouse sera.
erum cotinine levels were 13.85 ± 0.69 ng/mL, 20.22 ± 0.61 ng/mL,
99.67 ± 24.79 ng/mL, 37.56 ± 1.87 ng/mL, 372.37 ± 42.3 ng/mL,
6.75 ± 5.50 ng/mL in treatment with vehicle, erlotinib, erlotinib
lus nicotine (i.v.), erlotinib plus nicotine (oral), nicotine aloneicotine stimulation. Cells were serum-starved for 24 h, and then were exposed to
 (Ser 473), ERK in PC9 (B) and HCC827 (C) cells. Right panels: densitometric analysis
esults are presented as the means ± SEM of three independent experiments.
(i.v.) and nicotine alone (oral), respectively (P < 0.05; Fig. 4E).
No signiﬁcant difference was observed between erlotinib plus
nicotine (i.v.) and nicotine (i.v.) alone (P > 0.05).
3.5. Effects of erlotinib plus nicotine on signaling pathways in
tumor tissues
Since not much information is known about the relative con-
tribution of nicotine in NSCLC tumors, we excised tumor samples
in athymic mice on the last day of treatment for protein anal-
ysis (Fig. 5A). It is notable that erlotinib plus nicotine elevated
phosphorylated and total protein levels of EGFR, compared with
erlotinib alone (P < 0.05; Fig. 5B). Interestingly, this recovery effect
was much more obvious in acute nicotine exposure by i.v. injec-
tion than chronic nicotine exposure orally in the drinking water
(
P < 0.05). As previous studies showed nicotine induces PI3K/AKT
and MEK/ERK pathways in lung tumors [23,32], similar results
were obtained that chronic oral nicotine stimulation increased
the expression of phosphorylated AKT (Ser 473) under erlotinib
treatment (Fig. 5C). In contrast, no obvious upregulation of phos-
phorylated/total protein of ERK and total AKT were observed in
erlotinib plus nicotine stimulation compared with in erlotinib
treatment (Fig. 5C and D). In addition, we noticed that chronic
oral nicotine exposure signiﬁcantly unregulated the expression of
 1 nAChR in tumor tissues (*,,
P < 0.05; Fig. 5E). Collectively, our
data suggested that the cross-talk between nAChR and EGFR might
4 H. Li et al. / Lung Cancer 88 (2015) 1–8
Fig. 2. Nicotine induces resistance to erlotinib in PC9 and HCC827 cells in vitro. (A) PC9 (left panel) and HCC827 (right panel) cells were co-treated with erlotinib (0–5 M)
with  or without nicotine (1 M) for 72 h (relatively short-term exposure). Cell survival was  measured using MTS  assay, and was  expressed as a percentage of untreated
control. (B) IC50 values of erlotinib were calculated for each cell. **P < 0.01 for erlotinib plus nicotine compared with erlotinib alone. Results are presented as the means ± SEM
of  three independent experiments. ER, erlotinib; NIC, nicotine.
Fig. 3. Immunoblot analysis of cells incubated in the presence or absence of erlotinib for 1 h prior to exposure to 10 M nicotine for additional 1 h. Erlotinib inhibited
phosphorylation of EGFR, AKT (Ser 473), ERK, whereas stimulation with erlotinib (0.01 M) combined with nicotine elevated levels of phosphor- EGFR, AKT (Ser 473), ERK
in  PC9 (A) and HCC827 (B) cells. Cells treated with erlotinib (0.1 M)  plus nicotine did not show recovery of phosphorylated protein. Right panels: densitometric analysis of
western  blots for the phosphorylated protein. P < 0.05 for erlotinib (0.01 M)  plus nicotine compared with erlotinib (0.01 M)  alone. Data are presented as mean ± SEM of
three  independent experiments. ER, erlotinib; NIC, nicotine.
H. Li et al. / Lung Cancer 88 (2015) 1–8 5
Fig. 4. Nicotine increases tumor growth and induces resistance to erlotinib in the NSCLC xenograft model. (A) No substantial weight loss (≥20% of body weight at start of
treatment) was  observed in the mouse model during treatment. (B) Mice received vehicle or nicotine (0.6 mg/kg/5 times weekly i.v. injection; or 100 g/mL orally in the
drinking water) from day 3 after tumor implantation for 4 weeks. Both i.v. and oral exposure to nicotine promoted tumor growth compared with vehicle (*P < 0.05). Erlotinib
(100  mg/kg) combined with vehicle or nicotine (i.v./oral) treatments were started on day 21 after tumor implantation for additional 10 days. Erlotinib signiﬁcantly reduced
the  tumor size compared with control group (P < 0.05). The addition of nicotine to erlotinib treatment elevated tumor size compared with erlotinib alone (P < 0.05). In
addition, chronic oral nicotine administration in the drinking water induced more resistance to erlotinib compared with acute i.v. injection of nicotine (P < 0.05). (C) TGI %
by  erlotinib, erlotinib plus nicotine (i.v.), erlotinib plus nicotine (oral) in the xenograft model on the last day of treatment. (D) Macroscopic images of tumor tissues at the end
of  the study. (E) Concentration of cotinine (a biomarker for nicotine levels) in the mouse serum. Mouse blood were collected 30 min after nicotine i.v. injection on the last
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′ P < 0.05 for nicotine (i.v.) alone compared nicotine (oral) alon
resented as mean ± SEM of three independent experiments. ER, erlotinib; NIC, nic
e responsible for nicotine-promoted tumor growth and nicotine-
nduced resistance to erlotinib in NSCLC tumors.
. Discussion
Due to nicotine addiction, only a few percent of smokers quit
uccessfully each year [15]. NSCLC patients who continue to smoke,
r return to smoking, or have an second-hand smoke exposure,
ight experience tumor progression, resistance to therapy, higher
ecurrence rate after successful treatment and other risks of mor-
ality [5–9]. The activation of nAChR induced by nicotine might be
nvolved in those procedures [12–22]. It has been demonstrated
hat EGFR activity contributes to the growth and progression of
SCLC, and EGFR mutation status is one of important factors asso-
iated with response to EGFR-TKIs such as erlotinib [33]. Although
GFR mutations are less prevalent in NSCLC patients with smok-
ng history, several studies suggest the existence of cooperation
etween nAChR and EGFR in cancer progression [17,21,24].
Our previous results [24] have shown that nicotine  1 nAChR
lays an essential role in nicotine-induced cell signaling and
icotine-induced resistance to EGFR-TKI in the NSCLC PC9 cells.
n this study, we used nicotine with concentrations ranging fromh erlotinib alone; P < 0.05 for erlotinib plus nicotine (i.v.) compared with erlotinib
 > 0.05 for erlotinib plus nicotine (i.v.) compared with nicotine (i.v.) alone. Data are
10 nM to 10 M,  which are similar to the concentrations observed
in the bloodstream of smokers [19]. We demonstrated that nico-
tine could elevate the phosphorylated levels of EGFR/AKT/ERK
protein in a dose-dependent manner in NSCLCs. Indeed, nicotine
could induce resistance to erlotinib by activating EGFG/AKT/ERK
pathways. Additionally, nicotine could inhibit erlotinib-induced
apoptosis (Supplementary Fig. 1). Combined with the previous data
[24] that show siRNA against  1 nAChR can inhibit the activation
of EGFR/AKT/ERK pathways and decrease the resistance to EGFR-
TKI induced by nicotine in PC9 cells, the in vitro results conﬁrm
the relationship between  1 nAChR and EGFR in EGFR mutant
NSCLC cell lines. In accordance with reports [34,35], we also showed
that erlotinib had a concentration-dependent inhibition of growth
in the NSCLC PC9 and HCC827 cells with EGFR mutation. To our
knowledge, erlotinib plasma concentrations signiﬁcantly decrease
in smokers [36], suggesting the inhibition of erlotinib is more effec-
tive in non-smokers than in smokers with the same EGFR mutation
status. Besides, nicotine-activated nAChRs have been shown to
affect subsequent steps in the growth and metastasis of cancers
through inducing survival pathways [19]. We next established the
PC9 xenograft model exposed to vehicle/nicotine and then treated
mice with erlotinib.
6 H. Li et al. / Lung Cancer 88 (2015) 1–8
Fig. 5. (A) Immunoblot analysis of PC9 xenograft tumors treated with erlotinib in the presence or absence of nicotine. Tumor tissues of the xenograft model were collected
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AChR  protein (E). *P < 0.05 compared with control; P < 0.05 compared with erloti
oral).  Data are presented as mean ± SEM of three independent experiments. ER, er
Since the half-time of nicotine in mice (6–7 min) is much shorter
han that in humans (2 h) [37], i.v. injection of nicotine in mice
an mimic  a rapid increase of nicotine delivery to the circulation
fter smoking (inhaled nicotine), which is considered as an imme-
iate/acute exposure to nicotine after each injection/day. Because
ice are less sensitive to the acute effects of nicotine, relatively
igher dosage of nicotine (0.6 mg/kg) was used for i.v. injection in
ur study [37,38]. In contrast, nicotine orally in the drinking water
ould reproduce the cyclic increase and decrease of nicotine admin-
stration that occurs in smokers, because most drinking occurs
n the evening hours [39]. Combined with the suggested dosages
f nicotine for in vivo research and shorter half-time of nicotine
n mice [37], oral self-administration of nicotine at a low dose
100 g/mL) in the drinking water in mice could provide a sustained
nd steady-state level of nicotine in blood, which is a chronic nico-
ine exposure mimicking regular active smokers [39]. We  exposed
he mice to nicotine in two different ways of administration (i.v.
njection/day and oral in the drinking water) as immediate/acute
nd chronic exposure, respectively. Established xenograft models
ould reﬂect the similar situations in active/passive smokers.
Consistent with previous studies [11,28,40], our results showed
hat nicotine exposure can facilitate the growth of NSCLC PC9
umors already initiated. We  also demonstrated that nicotine expo-
ure can induce resistance to erlotinib through activating  1 nAChR
nd EGFR pathways in vivo. It is notable that chronic oral nico-
ine administration had more appreciable resistance to erlotinib
ompared with acute i.v. injection of nicotine. Importantly, chronic western blots for phosphorylated/total protein EGFR (B), AKT (C), ERK (D) and  1
ne; 
P < 0.05 for erlotinib plus nicotine (i.v.) compared with erlotinib plus nicotine
; NIC, nicotine.
nicotine exposure (weeks to months [41]) may  induce upregulation
of nAChR as reported [14,19,39]. Our results showed that  1 nAChR
was upregulated in response to chronic nicotine exposure, whereas
no obvious change was  observed in acute nicotine exposure. A
potential explanation is that the exceedingly high concentration of
nicotine (i.v. injection) can produce unanticipated effects, includ-
ing rapid and generalized receptor desensitization or even receptor
inactivation [39]. Further, route of nicotine administration can be
reﬂected by variable concentrations of nicotine [39]. Because of the
ﬁst-pass metabolism of nicotine via liver (in either humans or ani-
mal  models), only about 30% of orally administered nicotine can
reach the circulation. Thus, the cotinine levels measured from i.v.
delivery are indicative of a substantially higher exposure of the sys-
temic circulation to nicotine, compared with much lower cotinine
levels resulting from oral delivery.
The stimulation and upregulation of nAChRs induced by nicotine
seem to be responsible for diverse physiological effects targeting
the organs [14]. Nicotine binding to nAChRs induces the secretion
of growth factors such as EGF, which activates and regulates EGFR
and downstream pathways [19]. Interestingly, we provided the evi-
dence that chronic nicotine stimulation increased the expression of
phosphorylated AKT under erlotinib treatment, but not phospho-
rylated/total protein of ERK and total AKT. Nevertheless, no obvious
increase of phosphorylated AKT was observed in acute nicotine
stimulation, which may  be due to a condition that acute nicotine
exposure causes a rapid increase in receptor activation and/or pos-
sibly reduces receptor function. Notably, these results were not
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xactly the same with our in vitro results that showed nicotine
nduced resistance to erlotinib by activating both AKT and ERK
athways. These may  be in results of different time points for nico-
ine exposure [24], or the differences in nicotine metabolism in vitro
nd in vivo. In addition, AKT pathway is considered to be more
nvolved in nicotine-induced drug resistance, because the direct
ink between AKT pathway induced by nicotine and induction of
hemo-resistance has been proposed [12]. On the other hand, our
ata showed that acute nicotine exposure signiﬁcantly increased
oth phosphorylated and total protein of EGFR under erlotinib
reatment, compared with chronic nicotine exposure. These ﬁnd-
ngs may  explain, at least in part, the repeated but intermittent
njection of nicotine is fundamentally different from the more fre-
uently oral administration design. Considering to the high cotinine
oncentration in mouse serum after i.v. injection, nicotine could
apidly stimulate EGFR expression. Overall, it is possible that signal-
ng induced by nicotine may  contribute to differences in response
etween active/regular smokers (chronic/long-term nicotine expo-
ure) and passive smokers (acute/immediate nicotine exposure).
Cessation of smoking or avoiding second-hand smoke after diag-
osis improves multiple aspects of lung cancer including decreased
isk of second tumors, increased response to chemo/targeted
herapy agents [8]. In conclusion, our results demonstrated that
xposure to nicotine and activation of nAChR signaling not only
romote the tumor growth, but also render them resistant to ther-
peutic agents through the cooperation between nAChR and EGFR
athways. Besides quitting smoking, targeting  1 nAChR for pre-
enting resistance to targeted therapies is a potential alternative
ption for smokers and/or non-smokers patients with NSCLC. Fur-
her, more information about relationship between nAChRs and
GFR mutant NSCLC warrants evaluation.
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